BioPharma Resources

Drug Trial Radar · NCT04875169

Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

A Randomized, Double Blind and Placebo Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Jun 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

336

Actual

Start

Apr 30, 2021

Primary completion

Aug 12, 2022

Study completion May 23, 2023

Sponsor

Sponsor type
Industry
First posted
May 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 330 subjects aged 12 to 75 years old with moderate to severe atopic dermatitis.

Conditions

  • Atopic Dermatitis

Interventions

  • Core Treatment Active Experimental: SHR0302 Dose#1Drug

    Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks

  • Core Treatment Active Experimental: SHR0302 Dose#2Drug

    Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks

  • Core Treatment Placebo Comparator: PlaceboDrug

    Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks

  • Extension Treatment Active Experimental: SHR0302 Dose#1Drug

    Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks

  • Extension Treatment Active Experimental: SHR0302 Dose#2Drug

    Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator's Global Assessment (IGA) score of 0/1 at Week 16Time frame: 16 Weeks
  2. Eczema Area and Severity Index (EASI 75) at Week 16Time frame: 16 Weeks

Locations

52 sites in 2 countries. Site status is shown where the registry gives one.

  • Dermatology Research Institute Inc.

    Calgary, Alberta, Canada

  • Dr Chih-ho Hong Medical Inc.

    Surrey, British Columbia, Canada

  • Enverus Medical Research

    Surrey, British Columbia, Canada

  • Wiseman Dermatology Research

    Winnipeg, Manitoba, Canada

  • CCA Medical Research

    Ajax, Ontario, Canada

  • SKiN Health

    Cobourg, Ontario, Canada

  • DermEffects

    London, Ontario, Canada

  • North York Research Inc.

    North York, Ontario, Canada

  • The Centre for Dermatology

    Richmond Hill, Ontario, Canada

  • York Dermatology

    Richmond Hill, Ontario, Canada

  • Toronto Research Centre

    Toronto, Ontario, Canada

  • Research Toronto

    Toronto, Ontario, Canada

  • AvantDerm

    Toronto, Ontario, Canada

  • XLR8 Clinical Research

    Windsor, Ontario, Canada

  • Clinique D

    Laval, Quebec, Canada

  • Beijing Children's Hospital, Capital Medical University

    Beijing, China

  • Peking University third hospital

    Beijing, China

  • Peking union medical college hospital

    Beijing, China

  • Children's Hospital Capital Institute of Pediatrics

    Beijing, China

  • The Third Xiangya Hospital of Central South University

    Changsha, China

  • Chongqing Traditional Chinese medicine Hospital

    Chongqing, China

  • First affiliated hospital of chongqing medical university

    Chongqing, China

  • The Southwest Hospital of AMU

    Chongqing, China

  • Zhejiang province People's Hospital

    Hangzhou, China

  • Dermatology hospital of Shanghai

    Shanghai, China

  • Huashan Hospital Affiliated to Fudan University

    Shanghai, China

  • The first hospital of China medical university

    Shenyang, China

  • First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Peking University People's Hospital

    Beijing, Beiing, China

  • First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Zhongshan Hospital, Fudan University(Xiamen Branch)

    Xiamen, Fujian, China

  • Dermatology Hospital of Southern Medical University

    Guangzhou, Guangdong, China

  • Guangdong Province Traditional Chinese Medical Hospital

    Guangzhou, Guangdong, China

  • The First affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Wuhan No.1 Hospital

    Wuhan, Hubei, China

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Hospital for Skin Diseases, Chinese Academy of medical sciences

    Nanjing, Jiangsu, China

  • Jiangsu province people's hospital

    Nanjing, Jiangsu, China

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.